Correction: An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia

Neena Valecha; Aung Pyae Phyo; Mayfong Mayxay; Paul N. Newton; Srivicha Krudsood; Sommay Keomany; Maniphone Khanthavong; Tiengkham Pongvongsa; Ronnatrai Ruangveerayuth; Chirapong Uthaisil; David Ubben; Stephan Duparc; Antonella Bacchieri; Marco Corsi; Bappanad H. K. Rao; Prabash C. Bhattacharya; Nagesh Dubhashi; Susanta K. Ghosh; Vas Dev; Ashwani Kumar; Sasithon Pukrittayakamee

doi:10.1371/annotation/5603e1d7-03ca-4127-ab99-1d1e07d905d4

Neena Valecha,

Aung Pyae Phyo,

Mayfong Mayxay,

Paul N. Newton,

Srivicha Krudsood,

Sommay Keomany,

Maniphone Khanthavong,

Tiengkham Pongvongsa,

Ronnatrai Ruangveerayuth,

Chirapong Uthaisil,

David Ubben,

Stephan Duparc,

Antonella Bacchieri,

Marco Corsi,

Bappanad H. K. Rao,

Prabash C. Bhattacharya,

Nagesh Dubhashi,

Susanta K. Ghosh,

Vas Dev,

Ashwani Kumar,

[ ... ],

Sasithon Pukrittayakamee

[ view all ]

[ view less ]

Reader Comments

The second sentence in the Methods and Findings section of the Abstract contained an error. The sentence should read: Patients aged 3 months to 65 years with Plasmodium falciparum mono-infection or mixed infection were randomised with an allocation ratio of 2:1 to a fixed-dose DHA/PQP combination tablet (adults: 40 mg/320 mg; children: 20 mg/160 mg; n = 769) or loose combination of AS+MQ (AS: 50 mg, MQ: 250 mg; n = 381).

Citation: Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. (2010) Correction: An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia. PLoS ONE 5(9): 10.1371/annotation/5603e1d7-03ca-4127-ab99-1d1e07d905d4. https://doi.org/10.1371/annotation/5603e1d7-03ca-4127-ab99-1d1e07d905d4

Published: September 09, 2010

Copyright: © 2010 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing interests: No competing interests declared.